Latest Breaking News On - கிறிஸ்டின் ரோஜர்ஸ் - Page 5 : comparemela.com

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression February 12, 2021 19:41 ET | Source: G1 Therapeutics G1 Therapeutics - COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - - Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the need for rescue interventions such as growth factors and red blood cell transfusions - - G1 will host conference call Tuesday, February 16, 2021 at 8:00 a.m. ET - RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2021 (GLOBE NEWSWIRE) G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved COSELA�

Puerto ricoUnited statesJeffrey crawfordChristine rogersBonniej addarioJack baileyDuke cancer instituteBoehringer ingelheimDrug administrationExchange commissionTherapeutics incFoundation for lung cancerCorporate communicationsResearch triangle parkGeller professor for researchDepartment of medicine